12月24日 - ** 疫苗开发商DynavaxDVAX.O的股价盘前上涨37.6%至15.32美元，此前法国制药商赛诺菲SASY.PA表示将以22亿美元的价格收购DynavaxDVAX.O。
** 赛诺菲称将以每股 15.5 美元的价格收购该公司，与 DVAX 上次收盘价 11.13 美元相比，溢价 39.3
** 截至周二收盘，DVAX 的市值为 13.1 亿美元--LSEG 数据显示
** 收购资金将使用现有现金，不会对 25 财年财务前景产生影响 - 赛诺菲
** DVAX 的成人乙型肝炎疫苗和目前正在开发的带状疱疹疫苗将被纳入赛诺菲的产品线。
** 覆盖该股的 4 家券商中有 3 家给予 "买入 "或更高评级，1 家给予 "卖出 "评级- LSEG 数据
** 截至上次收盘，DVAX累计下跌近13
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.